Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested ...

Diversity and inclusion are critical to business success, particularly when fostering innovation and creativity. At Mednet, ...

A treatment that must be prescribed by a doctor and is not licensed for sale to the general public. A prescription medication is a licensed medicine that is regulated by law to necessitate a medical ...

GSK has received a recommendation from the European Medicines Agency’s human medicines committee for a single-vial, fully liquid presentation of its meningococcal vaccine Menveo. The new presentation, ...

Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...

The US Food and Drug Administration (FDA) has granted rare paediatric disease (RPD) designation to Enterprise Therapeutics’ investigational cystic fibrosis therapy. Estimated to affect more than ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people around the world. So, earlier this year, purpose consultancy Revolt launched ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been recommended by the European Medicines Agency’s human medicines committee to treat younger eosinophilic oesophagitis (EoE) patients. The Committee ...

Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...

UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...